Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of “Hold” by Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been given an average recommendation of “Hold” by the nineteen analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $13.8824.

A number of equities research analysts have issued reports on the stock. Wedbush increased their price objective on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arvinas in a research note on Friday, April 10th. BTIG Research raised their target price on Arvinas from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Wall Street Zen downgraded Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 target price (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th.

Insider Transactions at Arvinas

In other Arvinas news, Director John G. Houston sold 35,297 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $13.21, for a total value of $466,273.37. Following the sale, the director owned 1,122,183 shares of the company’s stock, valued at approximately $14,824,037.43. This trade represents a 3.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Noah Berkowitz sold 6,435 shares of the firm’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $11.10, for a total value of $71,428.50. Following the completion of the sale, the insider directly owned 202,503 shares in the company, valued at approximately $2,247,783.30. This represents a 3.08% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 63,864 shares of company stock worth $802,443. 4.73% of the stock is owned by insiders.

Institutional Investors Weigh In On Arvinas

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after purchasing an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares in the last quarter. State of Wyoming acquired a new stake in shares of Arvinas in the 3rd quarter valued at $68,000. Abel Hall LLC acquired a new stake in shares of Arvinas in the 4th quarter valued at $125,000. Finally, Corient Private Wealth LLC acquired a new stake in shares of Arvinas during the 4th quarter valued at $127,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Stock Down 1.7%

Shares of Arvinas stock opened at $10.81 on Thursday. The company has a market capitalization of $691.41 million, a price-to-earnings ratio of -8.45 and a beta of 1.97. Arvinas has a 12-month low of $5.90 and a 12-month high of $14.51. The firm’s 50-day moving average price is $11.84 and its two-hundred day moving average price is $11.62.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). The firm had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company’s quarterly revenue was down 84.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.63) earnings per share. On average, sell-side analysts expect that Arvinas will post -3.26 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.